[PDF][PDF] Analysis of anti-Omicron neutralizing antibody titers in different convalescent plasma sources
Analysis of anti-Omicron neutralizing antibody titers in different convalescent plasma sources
Page 1 1 Analysis of anti-Omicron neutralizing antibody titers in different convalescent plasma …
Page 1 1 Analysis of anti-Omicron neutralizing antibody titers in different convalescent plasma …
[HTML][HTML] Clinical application of SARS-CoV-2 antibody detection and monoclonal antibody therapies against COVID-19
J Sun, ZD Yang, X Xie, L Li, HS Zeng… - World Journal of …, 2023 - ncbi.nlm.nih.gov
The purpose of this study was to investigate the clinical application of severe acute
respiratory distress syndrome coronavirus-2 (SARS-CoV-2) specific antibody detection and …
respiratory distress syndrome coronavirus-2 (SARS-CoV-2) specific antibody detection and …
Deciphering cross-species reactivity of LAMP-1 antibodies using deep mutational epitope mapping and AlphaFold
T Pruvost, M Mathieu, S Dubois, B Maillère, E Vigne… - MAbs, 2023 - Taylor & Francis
Delineating the precise regions on an antigen that are targeted by antibodies has become a
key step for the development of antibody therapeutics. X-ray crystallography and cryogenic …
key step for the development of antibody therapeutics. X-ray crystallography and cryogenic …
Human genetic and immunological determinants of SARS‐CoV‐2 and Epstein–Barr virus diseases in childhood: Insightful contrasts
Q Pan‐Hammarström… - Journal of Internal …, 2023 - Wiley Online Library
There is growing evidence to suggest that severe disease in children infected with common
viruses that are typically benign in other children can result from inborn errors of immunity or …
viruses that are typically benign in other children can result from inborn errors of immunity or …
The relationship between SARS-CoV-2 neutralizing antibody titers and avidity in plasma collected from convalescent nonvaccinated and vaccinated blood donors
V Nurmi, C Knight, L Estcourt, J Hepojoki… - The Journal of …, 2023 - academic.oup.com
Convalescent plasma (CP) treatment of coronavirus disease 2019 (COVID-19) has shown
significant therapeutic effect when administered early (eg, Argentinian trial showing reduced …
significant therapeutic effect when administered early (eg, Argentinian trial showing reduced …
[HTML][HTML] Complete protection from SARS-CoV-2 lung infection in mice through combined intranasal delivery of PIKfyve kinase and TMPRSS2 protease inhibitors
Emerging variants of concern of SARS-CoV-2 can significantly reduce the prophylactic and
therapeutic efficacy of vaccines and neutralizing antibodies due to mutations in the viral …
therapeutic efficacy of vaccines and neutralizing antibodies due to mutations in the viral …
Human coronavirus OC43 nanobody neutralizes virus and protects mice from infection
A Adair, LL Tan, J Feng, J Girkin, N Bryant… - Journal of …, 2024 - Am Soc Microbiol
Human coronavirus (hCoV) OC43 is endemic to global populations and usually causes
asymptomatic or mild upper respiratory tract illness. Here, we demonstrate the neutralization …
asymptomatic or mild upper respiratory tract illness. Here, we demonstrate the neutralization …
Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate …
G Poulakou, PJ Royer, N Evgeniev, G Evanno… - Frontiers in …, 2024 - frontiersin.org
Introduction XAV-19 is a glyco-humanized swine polyclonal antibody targeting SARS-CoV-2
with high neutralizing activity. The safety and clinical efficacy of XAV-19 were investigated in …
with high neutralizing activity. The safety and clinical efficacy of XAV-19 were investigated in …
Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19
JG Ripoll, SM Tulledge-Scheitel, AA Stephenson… - Mbio, 2024 - Am Soc Microbiol
Although severe coronavirus disease 2019 (COVID-19) and hospitalization associated with
COVID-19 are generally preventable among healthy vaccine recipients, patients with …
COVID-19 are generally preventable among healthy vaccine recipients, patients with …
Cardiovascular adverse events associated with monoclonal antibody products in patients with COVID-19
J Zou, F Jing - Pharmaceuticals, 2022 - mdpi.com
Little is known about cardiovascular safety profiles for monoclonal antibody products that
received the FDA Emergency Use Authorization for COVID-19. In this study, data from the …
received the FDA Emergency Use Authorization for COVID-19. In this study, data from the …